Approval of Financial results for the Quarter and Year Ended March 31, 2026 and Recommendation of Final Dividend for the Year Ended March 31, 2026.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fortis Healthcare reported strong full-year results with revenue from operations growing 17.3% to Rs 912,784 lakhs from Rs 778,275 lakhs in the prior year. Net profit surged 31.5% to Rs 106,419 lakhs from Rs 80,938 lakhs. EBITDA increased 29% to Rs 213,564 lakhs with margins expanding from 21.3% to 23.4%. The Board recommended a final dividend of Rs 1 per equity share (10% on face value of Rs 10). Statutory auditors B S R & Co. LLP issued an unmodified (clean) audit opinion. The auditors included an emphasis of matter on ongoing SFIO investigation regarding alleged improper transactions from periods prior to 2018 and a Supreme Court order on RHT Health Trust transactions.
Strong operational performance with PAT growth of 31.5% and margin expansion should be positive for the stock. However, the ongoing regulatory investigations (SFIO and Supreme Court matters related to past promoter era) remain a risk factor for investors to monitor.